Sponsor

Central South University

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Central South University appears in 77 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials77
Recruiting shown13
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
tACS for Working Memory in SchizophreniaNCT07701343 · lead sponsor · 2026-07-06
RECRUITING
TIS for Improving Cognitive Impairment in SchizophreniaNCT07647380 · lead sponsor · 2026-06-24
RECRUITING
School and Family-Based Obesity Prevention in Pakistani Primary School ChildrenNCT07616232 · lead sponsor · 2025-12-08
RECRUITING
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia PatientsNCT07045142 · lead sponsor · 2025-07-01
RECRUITING
Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic AirspacesNCT07066813 · lead sponsor · 2025-06-01
RECRUITING
Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic AirspacesNCT07820423 · lead sponsor · 2025-05-01
RECRUITING
Immunoinflammatory State Detection and Multimodal Brain Imaging and Electrophysiologic Changes in SchizophreniaNCT06673966 · lead sponsor · 2025-01-10
RECRUITING
nTMS for Negative Symptom in SchizophreniaNCT06642675 · lead sponsor · 2024-11-22
RECRUITING
Multi-omics Study of Early-stage Lung Cancer With Distinct PhenotypesNCT06699979 · lead sponsor · 2024-08-29
RECRUITING
Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort StudyNCT06123897 · lead sponsor · 2024-01-01
RECRUITING
iTBS for Increased Appetite Induced by AntipsychoticsNCT05783063 · lead sponsor · 2023-08-01
RECRUITING
Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical ApplicationsNCT07444463 · lead sponsor · 2027-01-01
NOT_YET_RECRUITING
Temporal Interference Transcranial Alternating Current Stimulation for Major Depressive DisorderNCT07712159 · lead sponsor · 2026-10-10
NOT_YET_RECRUITING
Efficacy and Safety of Individualized Sequential Accelerated Theta Burst Stimulation in Improving Cognitive Function in SchizophreniaNCT07806877 · lead sponsor · 2026-09-30
NOT_YET_RECRUITING
TIS for Improving Cognitive Impairment Associated With SchizophreniaNCT07446478 · lead sponsor · 2026-06-24
COMPLETED
AKK Study in Improving Obesity and Metabolic Status in Children and AdolescentsNCT07593170 · lead sponsor · 2026-06-06
NOT_YET_RECRUITING
Neurobiological Mechanisms of Pathological Rumination and Effects of AripiprazoleNCT06937476 · lead sponsor · 2025-05-08
ACTIVE_NOT_RECRUITING
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan CapsulesNCT06749470 · lead sponsor · 2024-12-22
NOT_YET_RECRUITING
Investigating the Insulin Resistance in Individuals With Type 2 DiabetesNCT06428968 · lead sponsor · 2024-09-06
UNKNOWN
Exploring Sarcopenia in Parkinson's Disease Patients by Combining Serum Biomarker LevelsNCT06511531 · lead sponsor · 2024-08-01
UNKNOWN
Metformin Treatment on Cognitive Impairment of SchizophreniaNCT05838573 · lead sponsor · 2023-05-08
COMPLETED
iTBS on Negative Symptoms and Cognitive Function in SchizophreniaNCT05137158 · lead sponsor · 2022-10-15
COMPLETED
iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging.NCT05448430 · lead sponsor · 2022-07-15
UNKNOWN
aiTBS for Relieving NSSI in Depressive PatientsNCT05384405 · lead sponsor · 2022-07-01
UNKNOWN
Accelerated cTBS on Metabolic Dysfunction in People With SchizophreniaNCT05358899 · lead sponsor · 2022-06-01
UNKNOWN
A 6-month Study to Evaluate Sulforaphane Effects in PD PatientsNCT05084365 · lead sponsor · 2021-11-28
UNKNOWN
cTBS on First-episode Drug Naive Patients With SchizophreniaNCT05086133 · lead sponsor · 2021-11-20
UNKNOWN
Ai Youmian (Love Better Sleep) for People Living With HIVNCT05576844 · lead sponsor · 2021-09-28
COMPLETED
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in SchizophreniaNCT05039489 · lead sponsor · 2021-09-09
COMPLETED
Adjunctive Game Intervention for Anhedonia in MDD PatientsNCT04977232 · lead sponsor · 2021-09-09
COMPLETED
Resting State Electroencephalogram for Psychotic DisordersNCT05065489 · lead sponsor · 2021-09-01
UNKNOWN
rTMS on Appetite and Cognitive Function in SchizophreniaNCT04714970 · lead sponsor · 2021-04-20
UNKNOWN
Effects of MSC Intervention on the Dyadic Mental Health of Lung Cancer Patients and Their CaregiversNCT04795700 · lead sponsor · 2021-03-01
COMPLETED
Dyadic Psychological Stress Among Lung Cancer Patient-caregiver DyadsNCT06746948 · lead sponsor · 2021-01-01
COMPLETED
Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective DisordersNCT05840861 · lead sponsor · 2020-11-05
UNKNOWN
The Sensitivity and Specificity of Canine Detection of Parkinson's DiseaseNCT04613531 · lead sponsor · 2020-11-01
COMPLETED
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With AgomelatineNCT04589143 · lead sponsor · 2020-10-01
COMPLETED
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia PatientsNCT04521868 · lead sponsor · 2020-08-31
COMPLETED
Intervention Program to Address PTSD in People Living With HIVNCT05588596 · lead sponsor · 2020-05-03
COMPLETED
Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental DisordersNCT04218981 · lead sponsor · 2020-01-15
COMPLETED
Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking StudyNCT04071886 · lead sponsor · 2019-09-01
UNKNOWN
An Eye Tracking Study of Affective Disorder Patients With Suicide RiskNCT03711045 · lead sponsor · 2018-09-01
UNKNOWN
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic PatientsNCT03451734 · lead sponsor · 2018-01-23
COMPLETED
A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar DisorderNCT03379597 · lead sponsor · 2017-11-30
COMPLETED
Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic SyndromeNCT03271866 · lead sponsor · 2017-08-28
UNKNOWN
Mindful Living With Stress for Nurses Caring for HIV/AIDS Patients in ChinaNCT02936310 · lead sponsor · 2017-01-01
UNKNOWN
A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of SchizophreniaNCT02880462 · lead sponsor · 2016-12-26
COMPLETED
The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic SyndromeNCT02093858 · lead sponsor · 2014-04-01
UNKNOWN
Antipsychotic to Treat Psychosis SyndromeNCT02137616 · lead sponsor · 2012-06-01
UNKNOWN
A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in SchizophreniaNCT01490567 · lead sponsor · 2011-06-01
UNKNOWN
The Study of Minocycline for Negative and Cognitive Symptoms in SchizophreniaNCT01493622 · lead sponsor · 2010-06-01
COMPLETED
Metformin for Treatment of Antipsychotic-induced DyslipidemiaNCT01778244 · lead sponsor · 2008-11-01
COMPLETED
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in SchizophreniaNCT00859872 · lead sponsor · 2008-08-01
COMPLETED
Effects of Exposed to Antipsychotics Throughout Pregnancy on Infants Development: A Prospective StudyNCT01479400 · lead sponsor · 2007-10-01
COMPLETED
Effect of Adiponectin Genetic Polymorphism on Rosiglitazone ResponseNCT00501488 · lead sponsor · 2006-03-01
COMPLETED
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaNCT00654576 · lead sponsor · 2005-02-01
COMPLETED
Identification and Treatment of the Liability to Develop SchizophreniaNCT00305474 · lead sponsor · 2003-12-01
UNKNOWN
Belimumab After Rituximab in Resistant Primary Juvenile SSNCT06410833 · collaborator · 2024-03-09
RECRUITING
Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID RegistryNCT06417502 · collaborator · 2022-04-29
RECRUITING
Preoperative Anxiety and Depression Among Older Chinese PatientsNCT07744295 · collaborator · 2026-08-15
NOT_YET_RECRUITING

Drugs studied in this sponsor's trials

23 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Central South University as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo5
metformin3
escitalopram2
quetiapine2
risperidone2
acetylcysteine1
aripiprazole1
atorvastatin1
placebo RxCUI 8375 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 5 trials metformin RxCUI 6809 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials escitalopram RxCUI 321988 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials quetiapine RxCUI 51272 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials risperidone RxCUI 35636 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials acetylcysteine RxCUI 197 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial aripiprazole RxCUI 89013 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial atorvastatin RxCUI 83367 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial belimumab RxCUI 1092437 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial budesonide / formoterol RxCUI 389132 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial donepezil RxCUI 135447 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fluoxetine RxCUI 4493 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fluvoxamine RxCUI 42355 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial haloperidol RxCUI 5093 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial minocycline RxCUI 6980 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial olanzapine RxCUI 61381 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paroxetine RxCUI 32937 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial pilocarpine RxCUI 8328 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial proparacaine RxCUI 34905 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial risperidone Oral Solution RxCUI 373790 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial rituximab RxCUI 121191 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial rosiglitazone RxCUI 84108 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial vortioxetine RxCUI 1455099 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor57
collaborator20
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.